Summary:
- This article discusses the EU Orphan Drug Designation granted to Leads Biolabs' PDL141BB bispecific antibody, Opamtistomig (LBL024). This designation is a significant milestone, as it recognizes the potential of this drug to be a first-in-class therapy for a rare disease.
- Opamtistomig (LBL024) is a bispecific antibody that is designed to target and activate the immune system to fight against cancer cells. The Orphan Drug Designation will help accelerate the development and global patient access to this potential new treatment.
- The article highlights the importance of this designation in providing incentives and support for the development of therapies for rare diseases, which often have limited treatment options available.